CoChat

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity

Open access
Gallwitz, Baptist · 2022 · Frontiers in Endocrinology

The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.

Abstract

Incretin-based therapies with glucagon-like peptide-1 receptor agonists (GLP-1RA) are already established in the treatment of type 2 diabetes (T2D). The development of novel dual- or triple-receptor agonists that bind to the receptors not only for GLP-1 but also to the receptors for glucose-dependent insulinotropic polypeptide (GIP) and/or glucagon is intended to address different metabolic pathways for carbohydrate, lipid, and protein metabolism simultaneously. Dual- and triple-receptor agonists acting via different receptors and postreceptor pathways seem attractive in view of potentially additive or synergistic effects in the treatment of T2D and obesity. Recently, the first approval for a dual-receptor agonist marks an important step in this development. The GIP/GLP-1-receptor agonist tirzepatide was approved for the treatment of T2D by the Food and Drug Administration (FDA) in the USA for once-weekly subcutaneous injections in May 2022 and has just received a positive opinion from the European Medicines Agency (EMA). Tirzepatide dose-dependently leads to clinically significant reductions in glycemic parameters and body weight and has been shown to have stronger effects in reducing these parameters than standard antidiabetic therapy. This article summarizes the current clinical study program and the respective outcomes and highlights further potential indications for tirzepatide in the treatment of obesity and potentially other comorbidities of T2D.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2022.1004044

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Overview of the biological glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) effects at the organ/tissue level (modified from (47)). The blue arrows depict relevant physiological effects.
Figure 1 Overview of the biological glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) effects at the organ/tissue level (modified from (47)). The blue arrows depict relevant physiological effects.CC BY · PubMed Central
Figure 2 Amino acid sequence of tirzepatide in comparison to native GIP, GLP-1, and exendin-4 (exenatide). The amino acid sequences of the peptides are given in a one-letter code starting with the N-terminus on the left side. Å = Aib, alpha-amino-butyric acid; diacid-γ-Glu(AEFA)2, the linker molecule linking a fatty acid side chain with a length of 20 carbon atoms (=C20) to the K (lysine) in position 20; GLP-1, glucagon-like peptide-1; GIP, glucose-dependent insulinotropic polypeptide.
Figure 2 Amino acid sequence of tirzepatide in comparison to native GIP, GLP-1, and exendin-4 (exenatide). The amino acid sequences of the peptides are given in a one-letter code starting with the N-terminus on the left side. Å = Aib, alpha-amino-butyric acid; diacid-γ-Glu(AEFA)2, the linker molecule linking a fatty acid side chain with a length of 20 carbon atoms (=C20) to the K (lysine) in position 20; GLP-1, glucagon-like peptide-1; GIP, glucose-dependent insulinotropic polypeptide.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 76 references

Cited by

See all 87

Metadata

Authors
Gallwitz, B.
Affiliations
University of Tübingen (DE)
Corresponding author
Gallwitz, Baptist
Venue
Frontiers in Endocrinology
Published
2022-10-13
Volume
13
Pages
1004044-1004044
ISSN
1664-2392 (ISSN-L)
OpenAlex
W4306155811
Cited by
81
References
76
Citations by year
2026: 18 · 2025: 22 · 2024: 23 · 2023: 17 · 2022: 1
FWCI
2.24
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
tirzepatide, GIP/GLP-1 receptor agonist, type 2 diabetes, obesity, dual receptor agonist, incretin-based therapy, glycemic control, weight loss, glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, glucagon receptor, antidiabetic drug development
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Diabetes Mellitus, Type 2, Humans, Obesity, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. https://app.cochat.ai/papers/10.3389/fendo.2022.1004044
The paper
Gallwitz, B. (2022). Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2022.1004044

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.